Evaluation of the Use of Short Acting Insulin in the Management of Mild to Moderate Diabetic Ketoacidosis: A Simple Literature Review
Alnajrani, A., Al-Khilaifi, S., Aldhafeeri, S., Alqahtani, N., Alanazi, R., Shafaay, R., Saadi, S., Al-Hamoud, A., Alwagdani, H., Matari, N. (2018). Evaluation of the Use of Short Acting Insulin in the Management of Mild to Moderate Diabetic Ketoacidosis: A Simple Literature Review. EKB Journal Management System, 72(5), 4448-4453. doi: 10.21608/ejhm.2018.9502
Ali Abdullah Alnajrani; Suhaib Abdulrahman Al-Khilaifi; Sultan Salman Aldhafeeri; Nasser Falah Alqahtani; Reem Ahmed B. Alanazi; Rawan Adel Shafaay; Sufana Mohamedwageeh Saadi; Aishah Abdulrahman Al-Hamoud; Hadeel Salem Alwagdani; Naseem Ahmad Matari. "Evaluation of the Use of Short Acting Insulin in the Management of Mild to Moderate Diabetic Ketoacidosis: A Simple Literature Review". EKB Journal Management System, 72, 5, 2018, 4448-4453. doi: 10.21608/ejhm.2018.9502
Alnajrani, A., Al-Khilaifi, S., Aldhafeeri, S., Alqahtani, N., Alanazi, R., Shafaay, R., Saadi, S., Al-Hamoud, A., Alwagdani, H., Matari, N. (2018). 'Evaluation of the Use of Short Acting Insulin in the Management of Mild to Moderate Diabetic Ketoacidosis: A Simple Literature Review', EKB Journal Management System, 72(5), pp. 4448-4453. doi: 10.21608/ejhm.2018.9502
Alnajrani, A., Al-Khilaifi, S., Aldhafeeri, S., Alqahtani, N., Alanazi, R., Shafaay, R., Saadi, S., Al-Hamoud, A., Alwagdani, H., Matari, N. Evaluation of the Use of Short Acting Insulin in the Management of Mild to Moderate Diabetic Ketoacidosis: A Simple Literature Review. EKB Journal Management System, 2018; 72(5): 4448-4453. doi: 10.21608/ejhm.2018.9502

Evaluation of the Use of Short Acting Insulin in the Management of Mild to Moderate Diabetic Ketoacidosis: A Simple Literature Review

The Egyptian Journal of Hospital Medicine
Article 8, Volume 72, Issue 5, July 2018, Page 4448-4453  XML PDF (200.8 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2018.9502
View on SCiNiTO View on SCiNiTO
Authors
Ali Abdullah Alnajrani1; Suhaib Abdulrahman Al-Khilaifi2; Sultan Salman Aldhafeeri3; Nasser Falah Alqahtani4; Reem Ahmed B. Alanazi4; Rawan Adel Shafaay4; Sufana Mohamedwageeh Saadi5; Aishah Abdulrahman Al-Hamoud6; Hadeel Salem Alwagdani7; Naseem Ahmad Matari8
1Najran University
2Umm Al-Qura University
3Qassim University
4Almaarefa College
5Ibn Sina National College
6King Faisal University
7Taif University
8King Khalid University
Abstract
Background: Diabetes mellitus (DM) is one of the most common chronic diseases. It can cause a lot of complications such as retinopathy, nephropathy, and neuropathy. Patients with DM are at risk of having acute attacks of hyperglycemia and ketoacidosis as well as hypoglycemia. Diabetic ketoacidosis management is accomplished by the administration of intravenous infusion of regular insulin. Intravenous insulin infusion requires ICU admission in most of institutions, which will increase the hospitals cost (infusion pumps, IV access, nurses). Accordingly, we have done a literature study to determine whether intermittent subcutaneous use of these rapid-acting analogs might be as effective as intravenous insulin infusions in treating uncomplicated diabetic ketoacidosis.
Objective: In this study, we aimed at evaluating the effect of using short acting insulin in the management of mild to moderate DKA.
Methods: PubMed database was used for articles selection, and the following keys were used in the mesh ("Insulin Lispro"[Mesh]) AND ("Diabetic Ketoacidosis/drug therapy"[Mesh] OR "Diabetic Ketoacidosis/therapy"[Mesh]) A total of 13 articles were found, with further restriction by PubMed filters, and reviewing the articles titles and abstracts the final results were 5 articles.
Conclusion: Subcutaneous (S/C) Aspart insulin every 2 hours can be as safe and effective as SC Lispro insulin every one hour and as continuous IV insulin infusion in the treatment of mild to moderate uncomplicated cases of DKA. There was no significant statistical difference among the 3 approaches regarding the efficacy, and the mean duration of the treatment period. SC aspart insulin every 2 hours is more economical and fairer type intervention.
Keywords
Short acting insulin; Diabetic ketoacidosis; Evaluation; subcutaneous aspart insulin
Statistics
Article View: 247
PDF Download: 510